S9788, a new triazinoaminopiperidine derivative, was 250-fold more act
ive than verapamil in sensitizing DC-3F/AD cells to actinomycin D. Thi
s multidrug-resistance modulating activity of S9788 was confirmed on D
C-3F/AD, P388/ADR-10, P388/VCR-20, KB/A], K562/R, S1/tMDR, and COL0320
DM cells, with respect to actinomycin D, doxorubicin, vincristine, vin
blastine and etoposide. S9788 is 2-255-fold more active than verapamil
, depending on the cell line and the cytotoxic agent used, potentiatin
g preferentially the cytotoxicity of the vinca-alkaloid derivatives. S
9788 only had a slight effect on vincristine accumulation and retentio
n by parental sensitive cells, as well as on their sensitivity to cyto
toxic drugs. S9788 fully restored vincristine accumulation and retenti
on by S1/tMDR cells (S] cells transfected by the mdr 1 gene) to a leve
l similar to that measured in S1 cells, leading to a blockade in the G
2 + M phase of the cell cycle. Therefore, S9788 enhances vincristine a
ctivity by restoring its cellular accumulation in resistant cells. Aft
er a short incubation period of cells with vincristine (4 h), a condit
ion close to the clinical administration of this cytotoxic agent, a po
st-incubation for 20 hours more with 5 muM S9788, fully restored the s
ensitivity of S1/tMDR cells to vincristine. After an exposure of 4 hou
rs at equal concentrations, the accumulation of S9788 was 13-fold that
of verapamil in S1/tMDR cells, and 20 hours after the removal of the
modulators, S9788 was retained at a concentration 20-fold that of vera
pamil. S9788 is therefore a powerful new modifier of the P-gp-mediated
multidrug-resistance, which by its pharmacological properties (cellul
ar kinetics and activity), might be used in combination with existing
chemotherapy against tumors displaying the MDR phenotype.